Neurophet Showcases Advanced Brain Imaging Solutions at BIO USA 2025
Neurophet presents innovative solutions like 'Neurophet AQUA AD' for monitoring Alzheimer's treatment effects, aiming to strengthen global partnerships.
Neurophet, a leader in AI-driven brain health solutions, is set to participate in the BIO International Convention 2025 in Boston. The company will highlight its cutting-edge software, Neurophet AQUA AD, designed to monitor the effectiveness and side effects of Alzheimer's treatments. By analyzing MRI and PET scans, this technology supports clinical trials for drugs like Leqembi and Kisunla, addressing the growing need for precise brain imaging in Alzheimer's research. At the Korea Pavilion, Neurophet will also display its suite of neuroimaging tools, including Neurophet AQUA, SCALE PET, and tES LAB, along with the tES device, Neurophet innk. The company aims to expand its Contract Research Organization (CRO) services and partner with global pharmaceutical firms. Co-CEO Jake Junkil Been emphasized the potential of Neurophet AQUA AD in advancing biomarker development and companion diagnostics. BIO USA 2025, the world's largest biotech event, offers a platform for Neurophet to connect with over 1,500 companies and 20,000 attendees, driving innovation in brain health solutions through AI.